Nanjing Cavendish Bio-engineering Technology Co., Ltd.

Main objective: To evaluate and compare the pharmacokinetic characteristics of a single simultaneous oral administration of 20 mg 13C-102D-6 dry suspension and 20 mg mabaloxavir tablets or 20 mg 102D-6 dry suspension in healthy subjects under fasting conditions, to evaluate the relative bioavailability of 13C-102D-6 dry suspension and mabaloxavir tablets, the bioequivalence of 13C-102D-6 dry suspension and 102D-6 dry suspension, and to bridge the relative bioavailability of 102D-6 dry suspension to mabaloxavir tablets through 13C-102D-6 dry suspension. Secondary objectives: 1. To evaluate the safety and tolerability of a single oral dose of 13C-102D-6 dry suspension and 102D-6 dry suspension in healthy Chinese adult subjects, and compare them with mabaloxavir tablets; 2. To provide data support for the subsequent study of the dose design of 102D-6 and the bioequivalence, efficacy and safety bridge with mabaloxavir tablets; 3. To compare the plasma metabolites of 102D-6 dry suspension and mabaloxavir tablets.

Main objectives: 1. To evaluate the safety and tolerability of 102D-6 dry suspension after a single oral administration in healthy subjects; 2. To evaluate the effect of food on the pharmacokinetics of 102D-6 dry suspension. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of 102D-6 dry suspension after a single oral administration in healthy subjects; 2. To evaluate the safety of 102D-6 dry suspension after oral administration in healthy subjects in the postprandial state.

Main purpose: This study used metoclopramide tablets (specification: 10 mg) owned by Cavendish (Taizhou) Pharmaceutical Co., Ltd. and produced by Jiangsu Yuexing Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, metoclopramide tablets (specification: 10 mg, trade name: REGLAN®) owned by ANI PHARMACEUTICALS INC were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting conditions. Secondary purpose: Observe the safety of the test preparation metoclopramide tablets and the reference preparation metoclopramide tablets (REGLAN®) in healthy subjects.